Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Mesoporous Silica Coated Spions Containing Curcumin and Silymarin Intended for Breast Cancer Therapy Publisher Pubmed



Sadegha S1 ; Varshochian R2, 3 ; Dadras P4 ; Hosseinzadeh H1 ; Sakhtianchi R1 ; Mirzaie ZH2 ; Shafiee A1 ; Atyabi F1, 2 ; Dinarvand R1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Trita Nanomedicine Research Center (TNRC), Trita Third Millennium Pharmaceuticals, Zanjan, Iran

Source: DARU# Journal of Pharmaceutical Sciences Published:2022


Abstract

Introduction: Super-paramagnetic iron oxide nanoparticles (SPIONs) are known as promising theranostic nano-drug carriers with magnetic resonance imaging (MRI) properties. Applying the herbaceous components with cytotoxic effects as cargos can suggest a new approach in the field of cancer-therapy. In this study mesoporous silica coated SPIONs (mSiO2@SPIONs) containing curcumin (CUR) and silymarin (SIL) were prepared and evaluated on breast cancer cell line, MCF-7. Methods: Nanoparticles (NPs) were formulated by reverse microemulsion method and characterized by DLS, SEM and VSM. The in vitro drug release, cellular cytotoxicity, and MRI properties of NPs were determined as well. The cellular uptake of NPs by MCF-7 cells was investigated through LysoTracker Red staining using confocal microscopy. Results: The MTT results showed that the IC50 of CUR + SIL loaded mSiO2@SPIONs was reduced about 50% in comparison with that of the free drug mixture. The NPs indicated proper MRI features and cellular uptake through endocytosis. Conclusion: In conclusion the prepared formulation may offer a novel theranostic system for breast cancer researches. Graphical abstract: [Figure not available: see fulltext.] © 2022, The Author(s), under exclusive licence to Tehran University of Medical Sciences.